Advertisement

Clinical Rheumatology

, Volume 38, Issue 4, pp 1125–1130 | Cite as

Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients

  • Ozkan VaranEmail author
  • Hamit Kucuk
  • Hakan Babaoglu
  • Nuh Atas
  • Reyhan Bilici Salman
  • Hasan Satis
  • Mehmet Akif Ozturk
  • Seminur Haznedaroglu
  • Berna Goker
  • Abdurrahman Tufan
Original Article
  • 243 Downloads

Abstract

Background

Familial Mediterranean fever (FMF) patients suffer from chronic complications of disease such as AA amyloidosis, chronic arthritis, and spondylitis. Reduced quality of life (QoL) is a feature of chronic diseases but it is also impaired in patients with FMF. Despite the regular use of colchicine at a maximal dose, about 10% of patients do not respond well or resistant to colchicine (crFMF). IL-1 inhibitors have been shown to be effective in controlling attacks in crFMF patients. Herein, we aimed to investigate QoL changes of crFMF patients with IL-1 inhibitors.

Methods

All patients were prospectively monitored for the frequency, duration, severity of attacks, patient global assessments (Visual Analog Scale; VAS), and laboratory features. Either anakinra or canakinumab was used as IL-1 antagonist treatments. Demographic information, MEFV gene mutations, attack characteristics, and previous treatments were registered. Short form-36 (SF-36) quality of life scale was implemented by the interviewer for evaluating the QoL before and 3 months after the treatment.

Results

A total of 44 patients were included in this study. Striking improvements were detected in frequency, duration, and VAS severity of attacks (p < 0.001). In the comparison of pre- and post-treatment, SF-36 sub-components significant improvements were observed on physical function, role limitation due to physical difficulty, role limitation due to emotional problem, energy, emotional well-being, social function, pain, general health, and health change.

Conclusions

In conclusion, IL-1 antagonists prevent attacks and improve QoL of crFMF.

Keywords

Anakinra Canakinumab Familial Mediterranean fever IL-1 antagonist Quality of life 

Notes

Compliance with ethical standards

For use of IL-1 antagonists, off-label permission was obtained from regulatory authority and local ethics committee approved the study.

Disclosures

None.

References

  1. 1.
    Sari I, Birlik M, Kasifoglu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheumatol 1(1):21–33.  https://doi.org/10.5152/eurjrheum.2014.006 CrossRefGoogle Scholar
  2. 2.
    Shohat M, Halpern GJ (2011) Familial Mediterranean fever--a review. Genet Med 13(6):487–498.  https://doi.org/10.1097/GIM.0b013e3182060456 CrossRefGoogle Scholar
  3. 3.
    Tufan A, Ozturk MA (2017) Ailesel Akdeniz Ateşi: Güncel Tedavi Yaklaşımları. Turkiye Klinikleri J Rheumatol-Special Topics 10(1):37–45Google Scholar
  4. 4.
    Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651.  https://doi.org/10.1136/annrheumdis-2015-208690 CrossRefGoogle Scholar
  5. 5.
    Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 69(4):854–862.  https://doi.org/10.1002/art.39995 CrossRefGoogle Scholar
  6. 6.
    De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Kone-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919.  https://doi.org/10.1056/NEJMoa1706314 CrossRefGoogle Scholar
  7. 7.
    Varan O, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A (2018) Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol:1–4.  https://doi.org/10.1080/14397595.2018.1457469
  8. 8.
    Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, Katz SI, Kastner DL (2011) Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34(5):755–768.  https://doi.org/10.1016/j.immuni.2011.02.020 CrossRefGoogle Scholar
  9. 9.
    Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417–426CrossRefGoogle Scholar
  10. 10.
    Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R (2013) IL-1beta biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 45(1):117–130.  https://doi.org/10.1007/s12016-013-8358-y CrossRefGoogle Scholar
  11. 11.
    Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 34(7):1540–1544Google Scholar
  12. 12.
    Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroglu S, Onat AM (2011) Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 31(5):623–628.  https://doi.org/10.1007/s00296-009-1334-4 CrossRefGoogle Scholar
  13. 13.
    Giese A, Kurucay M, Kilic L, Ornek A, Sendur SN, Lainka E, Henning BF (2013) Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence. Rheumatol Int 33(7):1713–1719.  https://doi.org/10.1007/s00296-012-2622-y CrossRefGoogle Scholar
  14. 14.
    Press J, Neumann L, Abu-Shakra M, Bolotin A, Buskila D (2000) Living with a child with familial Mediterranean fever: does it affect the quality of life of the parents? Clin Exp Rheumatol 18(1):103–106Google Scholar
  15. 15.
    Sahin S, Yalcin I, Senel S, Ataseven H, Uslu A, Yildirim O, Semiz M (2013) Assesment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci 17(7):958–963Google Scholar
  16. 16.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885.  https://doi.org/10.1002/1529-0131(199710)40:10&lt;1879::AID-ART23&gt;3.0.CO;2-M CrossRefGoogle Scholar
  17. 17.
    Demiral Y, Ergor G, Unal B, Semin S, Akvardar Y, Kivircik B, Alptekin K (2006) Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health 6:247.  https://doi.org/10.1186/1471-2458-6-247 CrossRefGoogle Scholar
  18. 18.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I Conceptual framework and item selection. Med Care 30(6):473–483CrossRefGoogle Scholar
  19. 19.
    Kocyigit HAO, Fisek G, Olmez N, Memis A (1999) Validity and reliability of Turkish version of short form 36: a study of a patients with romatoid disorder. J Drug Ther (in Turkish) 12:102–106Google Scholar
  20. 20.
    Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, Langevitz P (1997) Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol 15(4):355–360Google Scholar
  21. 21.
    Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, Kasapcopur O, Kasifoglu T, Kisacik B, Ozdogan H, Tunca M, Acikel C, Vasculitis FMFA, Orphan disease research in pediatric r, Turkish FMFsg (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73(5):897–901.  https://doi.org/10.1136/annrheumdis-2013-204719 CrossRefGoogle Scholar
  22. 22.
    Gul A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S (2015) Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 17:243.  https://doi.org/10.1186/s13075-015-0765-4 CrossRefGoogle Scholar
  23. 23.
    Hashkes PJ, Spalding SJ, Hajj-Ali R, Giannini EH, Johnson A, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright D, Lovell DJ, Huang B (2014) The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int 2014:854842.  https://doi.org/10.1155/2014/854842 CrossRefGoogle Scholar
  24. 24.
    Duruoz MT, Unal C, Bingul DK, Ulutatar F (2018) Fatigue in familial Mediterranean fever and its relations with other clinical parameters. Rheumatol Int 38(1):75–81.  https://doi.org/10.1007/s00296-017-3882-3 CrossRefGoogle Scholar
  25. 25.
    Makay B, Emiroglu N, Unsal E (2010) Depression and anxiety in children and adolescents with familial Mediterranean fever. Clin Rheumatol 29(4):375–379.  https://doi.org/10.1007/s10067-009-1330-9 CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Ozkan Varan
    • 1
    Email author
  • Hamit Kucuk
    • 2
  • Hakan Babaoglu
    • 1
  • Nuh Atas
    • 1
  • Reyhan Bilici Salman
    • 1
  • Hasan Satis
    • 1
  • Mehmet Akif Ozturk
    • 1
  • Seminur Haznedaroglu
    • 1
  • Berna Goker
    • 1
  • Abdurrahman Tufan
    • 1
  1. 1.Faculty of Medicine, Department of Internal Medicine, Division of RheumatologyGazi UniversityAnkaraTurkey
  2. 2.Erzurum Regional Education and Research HospitalErzurumTurkey

Personalised recommendations